Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis

Studies analyzing human cancer genome sequences and genetically modified mouse models have extensively expanded our understanding of human tumorigenesis, even challenging or reversing the dogma of certain genes as originally characterized by in vitro studies. Inhibitor-κB kinase α (IKKα), which is e...

Full description

Bibliographic Details
Main Authors: Xin Li, Yinling Hu
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/6/1411
id doaj-eae97890e1d04b289a042376b4188dd9
record_format Article
spelling doaj-eae97890e1d04b289a042376b4188dd92021-03-20T00:04:45ZengMDPI AGCancers2072-66942021-03-01131411141110.3390/cancers13061411Attribution of NF-κB Activity to CHUK/IKKα-Involved CarcinogenesisXin Li0Yinling Hu1Laboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USALaboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USAStudies analyzing human cancer genome sequences and genetically modified mouse models have extensively expanded our understanding of human tumorigenesis, even challenging or reversing the dogma of certain genes as originally characterized by in vitro studies. Inhibitor-κB kinase α (IKKα), which is encoded by the conserved helix-loop-helix ubiquitous kinase (<i>CHUK</i>) gene, is first identified as a serine/threonine protein kinase in the inhibitor-κB kinase complex (IKK), which is composed of IKKα, IKKβ, and IKKγ (NEMO). IKK phosphorylates serine residues 32 and 36 of IκBα, a nuclear factor-κB (NF-κB) inhibitor, to induce IκBα protein degradation, resulting in the nuclear translocation of NF-κB dimers that function as transcriptional factors to regulate immunity, infection, lymphoid organ/cell development, cell death/growth, and tumorigenesis. NF-κB and IKK are broadly and differentially expressed in the cells of our body. For a long time, the idea that the IKK complex acts as a direct upstream activator of NF-κB in carcinogenesis has been predominately accepted in the field. Surprisingly, IKKα has emerged as a novel suppressor for skin, lung, esophageal, and nasopharyngeal squamous cell carcinoma, as well as lung and pancreatic adenocarcinoma (ADC). Thus, <i>Ikkα</i> loss is a tumor driver in mice. On the other hand, lacking the RANKL/RANK/IKKα pathway impairs mammary gland development and attenuates oncogene- and chemical carcinogen-induced breast and prostate tumorigenesis and metastasis. In general, NF-κB activation leads one of the major inflammatory pathways and stimulates tumorigenesis. Since IKKα and NF-κB play significant roles in human health, revealing the interplay between them greatly benefits the diagnosis, treatment, and prevention of human cancer. In this review, we discuss the intriguing attribution of NF-κB to CHUK/IKKα-involved carcinogenesis.https://www.mdpi.com/2072-6694/13/6/1411IKKαNF-κBCarcinogenesis
collection DOAJ
language English
format Article
sources DOAJ
author Xin Li
Yinling Hu
spellingShingle Xin Li
Yinling Hu
Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis
Cancers
IKKα
NF-κB
Carcinogenesis
author_facet Xin Li
Yinling Hu
author_sort Xin Li
title Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis
title_short Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis
title_full Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis
title_fullStr Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis
title_full_unstemmed Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis
title_sort attribution of nf-κb activity to chuk/ikkα-involved carcinogenesis
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2021-03-01
description Studies analyzing human cancer genome sequences and genetically modified mouse models have extensively expanded our understanding of human tumorigenesis, even challenging or reversing the dogma of certain genes as originally characterized by in vitro studies. Inhibitor-κB kinase α (IKKα), which is encoded by the conserved helix-loop-helix ubiquitous kinase (<i>CHUK</i>) gene, is first identified as a serine/threonine protein kinase in the inhibitor-κB kinase complex (IKK), which is composed of IKKα, IKKβ, and IKKγ (NEMO). IKK phosphorylates serine residues 32 and 36 of IκBα, a nuclear factor-κB (NF-κB) inhibitor, to induce IκBα protein degradation, resulting in the nuclear translocation of NF-κB dimers that function as transcriptional factors to regulate immunity, infection, lymphoid organ/cell development, cell death/growth, and tumorigenesis. NF-κB and IKK are broadly and differentially expressed in the cells of our body. For a long time, the idea that the IKK complex acts as a direct upstream activator of NF-κB in carcinogenesis has been predominately accepted in the field. Surprisingly, IKKα has emerged as a novel suppressor for skin, lung, esophageal, and nasopharyngeal squamous cell carcinoma, as well as lung and pancreatic adenocarcinoma (ADC). Thus, <i>Ikkα</i> loss is a tumor driver in mice. On the other hand, lacking the RANKL/RANK/IKKα pathway impairs mammary gland development and attenuates oncogene- and chemical carcinogen-induced breast and prostate tumorigenesis and metastasis. In general, NF-κB activation leads one of the major inflammatory pathways and stimulates tumorigenesis. Since IKKα and NF-κB play significant roles in human health, revealing the interplay between them greatly benefits the diagnosis, treatment, and prevention of human cancer. In this review, we discuss the intriguing attribution of NF-κB to CHUK/IKKα-involved carcinogenesis.
topic IKKα
NF-κB
Carcinogenesis
url https://www.mdpi.com/2072-6694/13/6/1411
work_keys_str_mv AT xinli attributionofnfkbactivitytochukikkainvolvedcarcinogenesis
AT yinlinghu attributionofnfkbactivitytochukikkainvolvedcarcinogenesis
_version_ 1724212404188872704